Russian Federation to start human trials of another COVID-19 vaccine
Jul 01 2020
Bharat Biotech has developed COVAXIN in association with ICMR's National Institute of Virology (NIV) Pune. Pointing out that results from preclinical studies on animals have been promising and show extensive safety and effective immune responses, Bharat Biotech CMD Dr Krishna Ella said the results of trials should be out by October 2020. The proactive support and guidance from CDSCO have enabled approvals to this project.
Ahmedabad-based Cadila Healthcare was the first among Indian players to announce a vaccine candidate - it had also started pre-clinical studies.
J&J has joined hands with the U.S. government for a $1 billion investment to speed up development and production of its vaccine.
Earlier this month, the AstraZeneca CEO told a radio station that the vaccine candidate would likely provide protection against Covid-19 for one year.
The company's Ad5-nCoV vaccine candidate has also won approval in human testing in Canada.
According to the World Health Organisation (WHO), there are 16 vaccine candidates now in late-stage clinical trials among the 140 vaccines in different stages of development to fight COVID-19.
The FDA strongly encourages the inclusion of diverse populations in all phases of clinical development, including populations most affected by COVID-19, specifically racial and ethnic minorities, as well as adequate representation in late phase trials of elderly individuals and those with medical comorbidities. "We are expanding our global manufacturing capacity, including establishing new vaccine manufacturing capabilities", Stoffels said in an email interview from Belgium.
Apart from Bharat Biotech, Zydus Cadilla is working on two vaccines, while Biological E, Indian Immunologicals, and Mynvax are developing a vaccine each. Believe it or not, these herbs do play a significant role in the treatment of COVID-19 patients.